RDEA Related Analyst Comments
-
Jefferis Remains Positive on Shares of Ardea Biosciences (RDEA) Following 28-Week Extension Data For Lesinurad-Allopurinol Combination
-
Jefferies Raises Price Target on Ardea Biosciences (RDEA), Maintains Buy Rating
-
Global Hunter Securities reiterates a 'Buy' on Ardea Biosciences (RDEA); Positive top-line Phase IIb RDEA594 Data
-
Brean Murray Carret & Co. Raises Price Target on Ardea Biosciences (RDEA)
-
Jefferies Raises Ardea Biosciences's (RDEA) Price Target to $30, Maintains Rating at Buy
-
Leerink Swann Says M&A Is One Reason To Get Involved In Biophama (AGN, DNDN, BMRN, HGSI, more...)
-
Leerink Swann Reiterates an 'Outperform' on Ardea Biosciences (RDEA); Positive Phase IIb Data for RDEA594 Monotherapy De-Risks Gout Program
-
Soleil Securities Reiterates a 'Buy' Rating on Ardea Biosciences (RDEA)
-
Brean Murray Raises Price Target on Ardea (RDEA) to $23; Sees Phase 2b Trials on RDEA594 Proving It Is a 'Safe and Effective Drug'
Back to RDEA Stock Lookup
